These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 31949093)
1. Retinal vessel diameter changes after 6 months of treatment in the Idiopathic Intracranial Hypertension Treatment Trial. Moss HE; Hollar RA; Fischer WS; Feldon SE Br J Ophthalmol; 2020 Oct; 104(10):1430-1434. PubMed ID: 31949093 [TBL] [Abstract][Full Text] [Related]
2. Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial. ; Ophthalmology; 2015 Sep; 122(9):1939-45.e2. PubMed ID: 26198807 [TBL] [Abstract][Full Text] [Related]
3. The Relationship Between Optic Disc Volume, Area, and Frisén Score in Patients With Idiopathic Intracranial Hypertension. Sheils CR; Fischer WS; Hollar RA; Blanchard LM; Feldon SE; Am J Ophthalmol; 2018 Nov; 195():101-109. PubMed ID: 30081012 [TBL] [Abstract][Full Text] [Related]
4. Intracranial pressure affects retinal venular complexity in idiopathic intracranial hypertension: a retrospective observational study. Cao L; Wang H; Kwapong WR; Xiong Z; Zhao Y; Liu G; Liu R; Liu J; Hu F; Wu B BMC Neurol; 2024 Oct; 24(1):402. PubMed ID: 39427135 [TBL] [Abstract][Full Text] [Related]
5. Peripapillary Retinal Pigment Epithelium Layer Shape Changes From Acetazolamide Treatment in the Idiopathic Intracranial Hypertension Treatment Trial. Wang JK; Kardon RH; Ledolter J; Sibony PA; Kupersmith MJ; Garvin MK; Invest Ophthalmol Vis Sci; 2017 May; 58(5):2554-2565. PubMed ID: 28492874 [TBL] [Abstract][Full Text] [Related]
6. Impact of weight reduction on structural and functional parameters of the optic nerve in idiopathic intracranial hypertension. Banerjee M; Phuljhele S; Saxena R; Sharma P; Misra V; Vibha D; Pandit AK Eur J Ophthalmol; 2024 Sep; 34(5):1594-1599. PubMed ID: 38380874 [TBL] [Abstract][Full Text] [Related]
7. Optic disc haemorrhages at baseline as a risk factor for poor outcome in the Idiopathic Intracranial Hypertension Treatment Trial. Wall M; Thurtell MJ; Br J Ophthalmol; 2017 Sep; 101(9):1256-1260. PubMed ID: 28130349 [TBL] [Abstract][Full Text] [Related]
8. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. ; Wall M; McDermott MP; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; Kupersmith MJ JAMA; 2014 Apr 23-30; 311(16):1641-51. PubMed ID: 24756514 [TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. ten Hove MW; Friedman DI; Patel AD; Irrcher I; Wall M; McDermott MP; J Neuroophthalmol; 2016 Mar; 36(1):13-9. PubMed ID: 26587993 [TBL] [Abstract][Full Text] [Related]
10. OCT measurements of optic nerve head changes in idiopathic intracranial hypertension. Huang-Link YM; Al-Hawasi A; Oberwahrenbrock T; Jin YP Clin Neurol Neurosurg; 2015 Mar; 130():122-7. PubMed ID: 25614195 [TBL] [Abstract][Full Text] [Related]
11. The Effect of Treatment of Idiopathic Intracranial Hypertension on Prevalence of Retinal and Choroidal Folds. Kupersmith MJ; Sibony PA; Feldon SE; Wang JK; Garvin M; Kardon R; Am J Ophthalmol; 2017 Apr; 176():77-86. PubMed ID: 28040526 [TBL] [Abstract][Full Text] [Related]
12. Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial. Cello KE; Keltner JL; Johnson CA; Wall M; J Neuroophthalmol; 2016 Mar; 36(1):6-12. PubMed ID: 26618282 [TBL] [Abstract][Full Text] [Related]
13. The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes. Smith SV; Friedman DI Headache; 2017 Sep; 57(8):1303-1310. PubMed ID: 28758206 [TBL] [Abstract][Full Text] [Related]
14. The Effect of Acetazolamide and Weight Loss on Intraocular Pressure in Idiopathic Intracranial Hypertension Patients. Banik R; Kupersmith MJ; Wang JK; Garvin MK; J Glaucoma; 2019 Apr; 28(4):352-356. PubMed ID: 30624392 [TBL] [Abstract][Full Text] [Related]
15. CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. Kattah JC; Pula JH; Mejico LJ; McDermott MP; Kupersmith MJ; Wall M J Neurol; 2015 Oct; 262(10):2271-4. PubMed ID: 26159101 [TBL] [Abstract][Full Text] [Related]
16. Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Wall M; Johnson CA; Cello KE; Zamba KD; McDermott MP; Keltner JL; Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):805-12. PubMed ID: 26934136 [TBL] [Abstract][Full Text] [Related]
17. Quality of life at 6 months in the Idiopathic Intracranial Hypertension Treatment Trial. Bruce BB; Digre KB; McDermott MP; Schron EB; Wall M; Neurology; 2016 Nov; 87(18):1871-1877. PubMed ID: 27694262 [TBL] [Abstract][Full Text] [Related]
18. Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. Albrecht P; Blasberg C; Ringelstein M; Müller AK; Finis D; Guthoff R; Kadas EM; Lagreze W; Aktas O; Hartung HP; Paul F; Brandt AU; Methner A J Neurol; 2017 Jul; 264(7):1370-1380. PubMed ID: 28584914 [TBL] [Abstract][Full Text] [Related]
19. Magnetic Resonance Imaging of Idiopathic Intracranial Hypertension: Before and After Treatment. Batur Caglayan HZ; Ucar M; Hasanreisoglu M; Nazliel B; Tokgoz N J Neuroophthalmol; 2019 Sep; 39(3):324-329. PubMed ID: 31430269 [TBL] [Abstract][Full Text] [Related]